Scholarlink

<p>The evolutionary dynamics of biliary tract cancer (BTC)—from precancerous transformation through metastatic dissemination and recurrence—remain poorly understood. We performed multi-regional and longitudinal whole-exome sequencing of 55 tumor specimens and 17 matched normals from 17 patients to reconstruct patient-specific phylogenetic trees and mutational signatures. <i>TP53</i> (41.2%), <i>KRAS</i> (29.4%), and <i>SMAD4</i> (23.5%) were the most frequently altered genes in primary tumors. Precancerous biliary intraepithelial neoplasia already harbored canonical driver mutations such as <i>TP53</i> and <i>KRAS</i>, showing early branching and selective sweeps during malignant transition. During metastasis, distinct subclones expanded more than fivefold in 15 of 17 patients, frequently harboring driver-like alterations (e.g., <i>NFKB1</i>, <i>MAPK7</i>, <i>PIK3C2A</i>). Postoperative recurrences retained the phylogenetic structure of the primary tumor, supporting polyclonal rather than single-cell seeding. Mutational signatures associated with 5-fluorouracil (SBS17b) and platinum (SBS35) were enriched in recurrent/metastatic lesions, suggesting that chemotherapy may shape the tumor mutational landscape. Druggable targets—including <i>ERBB2</i> amplification and <i>KRAS</i> mutations—were maintained through recurrence and metastasis when present at diagnosis. These findings reveal a consistent evolutionary program in BTC, encompassing early clonal diversification, subclonal expansion during metastasis, and polyclonal recurrence, underscoring the need for evolution-informed therapeutic strategies that address both clonal and subclonal alterations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Shared evolutionary trajectories underlying carcinogenesis and metastasis in biliary tract cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Minsu Kang,
  • Ju Hyun Lee,
  • Hee Young Na,
  • Ji-Won Kim,
  • Sejoon Lee,
  • Kui-Jin Kim,
  • Songji Choi,
  • Woochan Park,
  • Jeongmin Seo,
  • Heejung Chae,
  • Eun Hee Jung,
  • Koung Jin Suh,
  • Yejee Lim,
  • Se Hyun Kim,
  • Jin Won Kim,
  • Yu Jung Kim,
  • Yoo-Seok Yoon,
  • Jee Hyun Kim,
  • Ho-Seong Han,
  • Keun-Wook Lee

摘要

The evolutionary dynamics of biliary tract cancer (BTC)—from precancerous transformation through metastatic dissemination and recurrence—remain poorly understood. We performed multi-regional and longitudinal whole-exome sequencing of 55 tumor specimens and 17 matched normals from 17 patients to reconstruct patient-specific phylogenetic trees and mutational signatures. TP53 (41.2%), KRAS (29.4%), and SMAD4 (23.5%) were the most frequently altered genes in primary tumors. Precancerous biliary intraepithelial neoplasia already harbored canonical driver mutations such as TP53 and KRAS, showing early branching and selective sweeps during malignant transition. During metastasis, distinct subclones expanded more than fivefold in 15 of 17 patients, frequently harboring driver-like alterations (e.g., NFKB1, MAPK7, PIK3C2A). Postoperative recurrences retained the phylogenetic structure of the primary tumor, supporting polyclonal rather than single-cell seeding. Mutational signatures associated with 5-fluorouracil (SBS17b) and platinum (SBS35) were enriched in recurrent/metastatic lesions, suggesting that chemotherapy may shape the tumor mutational landscape. Druggable targets—including ERBB2 amplification and KRAS mutations—were maintained through recurrence and metastasis when present at diagnosis. These findings reveal a consistent evolutionary program in BTC, encompassing early clonal diversification, subclonal expansion during metastasis, and polyclonal recurrence, underscoring the need for evolution-informed therapeutic strategies that address both clonal and subclonal alterations.